Latest News Archive
Please select Category, Year, and then Month to display items
14 November 2024
|
Story André Damons
|
Photo André Damons
Staff members from the Directorate Research Development (DRD) at the University of the Free State; Palesa Mgaga, second from right, Tebogo Machethe, centre, and Charelise van Staden, second from right, were thanked for hosting the launch of the Khoebo Innovation Promotion Programme. They are pictured with colleagues from the IDC’s Samkelisiwe Mtsewu, left, and Thato Mogopodi, far right.
The University of the Free State (UFS), represented by the Directorate Research Development (DRD), played host to the Department of Trade Industry and Competition (dtic) and the Industrial Development Corporation (IDC) for the launch of its Khoebo Innovation Promotion Programme (KIPP).
The launch took place on 5 November in the Sasol Library on the Bloemfontein Campus. Tebogo Machethe, Director: Research Contracts and Innovation at the DRD, said its role was to expose the university researchers to different opportunities and programmes for funding from the IDC and the dtic. It also allowed the researchers to engage potential funders in order to understand what funders look for in a project when considering funding it.
“The aim of IDC KIPP is to assist local entrepreneurs and small to medium enterprises with commercialisation funding. The KIPP offers capital and business support to SMMEs during the early stages of commercialisation with particular emphasis on township and rural entrepreneurs,” said Machethe.
Address uneven distribution of economic development
KIPP is a dtic programme but is managed by the IDC and aims to enable early-stage innovative SMEs to penetrate the market with their locally developed innovations, resulting in a more competitive economic environment and thereby facilitating economic growth in the economy.
According to Machethe, who welcomed the guests, participants and presenters to the launch, some of the funding is geared towards the development of university innovations. Though the focus was on the KIPP launch, he continued, the discussions also encompassed other forms of funding that are available and more geared towards the university innovation.
His address was centred around the university's Vision 130 and how it supports innovation and the entire innovation ecosystem, which seeks to shift the emphasis to research impact, embracing both knowledge and societal impact. Vision 130 identifies the need for a greater focus on collaborative research, research that can attract large-scale funding in niche areas where the university is seen as a national and global leader.
Samkelisiwe Mtsewu, KIPP Account Manager at the IDC, said the programme was introduced to address the uneven distribution of economic development across the country. She said with its capacity, the KIPP programme can contribute to addressing the uneven distribution of economic development.
UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08
The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.
The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.
The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.
“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.
“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.
According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.
The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.
According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.
The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.
Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004